Reference: CEPI. (2022, October). COVID-19 AESI including status of associated Brighton case definitions. Retrieved from [insert URL here] Summary: The document presents an updated list of Adverse Events Following Immunisation (AESI) related to COVID-19, alongside their Brighton case definitions. It categorises various conditions such as acute respiratory distress syndrome, myocarditis, and thrombosis, indicating their publication […]
Summary The document outlines Dr Peter McCullough’s serious concerns about the safety of COVID 19 vaccines, particularly in children. Dr McCullough, an expert in cardiology and internal medicine with a wealth of experience in medical research and publications, argues that the vaccines may carry risks and questions the accuracy of the data used for their
Reference: CEPI. (2021). COVID-19 associated events of special interest including status of associated Brighton case definitions. Retrieved from https://docs.google.com/spreadsheets/d/1QgF35nYcsaFN3DZTOtV_lP0TYqQzsDMUQBAd5M9brrM/edit#gid=1666959512 Summary: This document provides an overview of COVID-19 associated events of special interest (AESI) alongside their Brighton case definitions as of October 2021. It categorises AESIs into three groups: those seen with COVID-19 disease, those with
Reference: Kennedy, R. F., & Nass, M. (2021). Concerns over COVID-19 vaccination for children aged 5-11. Retrieved from Children’s Health Defense. Summary: In a letter to the FDA and VRBPAC members, Children’s Health Defense (CHD) expressed strong opposition to the potential Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine for children aged 5-11. The
Summary The affidavit, signed by a UK based medical practitioner, raises concerns about the Covid vaccine’s safety for those under 18. The expert cites data showing an increase in deaths among males aged 15 19 post vaccination. They argue that the vaccine may be causing these excess deaths, especially as it aligns with trends in
Reference: Public Health Scotland. (2021). COVID-19 statistical report: As at 18 October 2021. Retrieved from https://www.publichealthscotland.scot/ Summary: The Public Health Scotland COVID-19 Statistical Report, published on 20 October 2021, provides a comprehensive overview of COVID-19 incidence and related data in Scotland. As of 17 October 2021, there were 609,959 confirmed cases, with a notable decrease
Reference: Wolfe, R. (2021, October 21). Fully vaccinated were the majority of COVID deaths in Sweden, UK in September. LifeSite. https://www.lifesitenews.com/news/fully-vaccinated-people-now-the-majority-of-covid-deaths-in-uk-sweden/ Summary: Recent data from Sweden and the UK reveals that “fully vaccinated” individuals comprised the majority of COVID-19 deaths in September 2021. In Sweden, 70% of COVID fatalities between September 1-24 were among fully
Reference: European Medicines Agency (2021). Assessment report on the annual renewal of the conditional marketing authorisation for Comirnaty (COVID-19 mRNA vaccine). EMA/596333/2021. Summary: The European Medicines Agency (EMA) conducted an assessment for the annual renewal of the conditional marketing authorisation (CMA) for Comirnaty, a COVID-19 mRNA vaccine developed by BioNTech. Originally granted on 21 December
Reference: European Medicines Agency. (2021). Assessment report on the annual renewal of the conditional marketing authorisation. EMA/596333/2021. Summary: The European Medicines Agency (EMA) assessed the annual renewal of the conditional marketing authorisation for Comirnaty, a COVID-19 mRNA vaccine developed by BioNTech. Initially granted on 21 December 2020, the renewal process involved reviewing specific obligations (SOBs)
Reference: FLCCC Alliance. (2021). I-MASK+ protocol: Prevention and early outpatient treatment protocol for COVID-19 (Version 18). Retrieved from https://www.flccc.net/covid-19-protocols Summary: The I-MASK+ protocol, developed by the Front Line COVID-19 Critical Care Alliance (FLCCC), is designed for the prevention and early outpatient treatment of COVID-19, particularly against the Delta variant. It emphasises the use of ivermectin